Shares of USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) gapped up before the market opened on Wednesday after the company announced better than expected quarterly earnings. The stock had previously closed at $31.96, but opened at $35.67. USANA Health Sciences shares last traded at $32.93, with a volume of 84,067 shares trading hands.
The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The company had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on USNA shares. Sidoti downgraded shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th. StockNews.com lowered shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th. Finally, DA Davidson dropped their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday.
View Our Latest Stock Report on USNA
Institutional Investors Weigh In On USANA Health Sciences
Several institutional investors and hedge funds have recently made changes to their positions in USNA. Pacer Advisors Inc. boosted its position in shares of USANA Health Sciences by 16.5% during the 3rd quarter. Pacer Advisors Inc. now owns 544,256 shares of the company's stock valued at $20,638,000 after purchasing an additional 76,904 shares in the last quarter. Pzena Investment Management LLC boosted its holdings in USANA Health Sciences by 7.5% in the third quarter. Pzena Investment Management LLC now owns 1,049,610 shares of the company's stock worth $39,801,000 after acquiring an additional 72,977 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in USANA Health Sciences by 7.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock worth $27,751,000 after acquiring an additional 55,059 shares in the last quarter. Jane Street Group LLC boosted its holdings in USANA Health Sciences by 330.0% in the fourth quarter. Jane Street Group LLC now owns 39,979 shares of the company's stock worth $1,435,000 after acquiring an additional 30,681 shares in the last quarter. Finally, Norges Bank bought a new position in USANA Health Sciences in the fourth quarter worth approximately $953,000. Institutional investors and hedge funds own 54.25% of the company's stock.
USANA Health Sciences Price Performance
The firm has a fifty day simple moving average of $33.50 and a 200-day simple moving average of $36.56. The firm has a market cap of $563.22 million, a P/E ratio of 10.44, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Stories
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
